Table 3.
Clinical and lab characteristics
| Challenge Severity Score (CSS) | |||||||
|---|---|---|---|---|---|---|---|
|
|
|||||||
| 1 (n=15) | 2 (n=44) | 3 (n=39) | 4 (n=9) | 5,6‡ (n=13) | Total (N=120) | P-value * | |
| FEV1 % at DBPCFC, mean (SD) | 94.5 (10.1) | 97.5 (12.9) | 94.7 (11.2) | 91.1 (7.6) | 94.7 (13.1) | 95.5 (11.7) | 0.72 |
| FEV1/FVC at DBPCFC, mean (SD) | 0.86 (0.07) | 0.86 (0.07) | 0.82 (0.07) | 0.80 (0.08) | 0.82 (0.06) | 0.84 (0.07) | 0.02 |
| Peanut wheal size (mm), mean (SD) | 12.2 (7.45) | 13.3 (6.4) | 13.4 (5.6) | 12.7 (5.8) | 13.5 (7.1) | 13.3 (6.1) | 0.96 |
| Complete Blood Count, mean (SD) | |||||||
| Absolute Basophil Count | 0.05 (0.03) | 0.04 (0.03) | 0.04 (0.02) | 0.04 (0.02) | 0.04 (0.01) | 0.04 (0.02) | 0.90 |
| Absolute Neutrophil Count | 3.3 (1.2) | 2.9 (1.3) | 3.2 (1.4) | 3.7 (1.1) | 3.2 (1.8) | 3.1 (1.4) | 0.17 |
| Absolute Lymphocyte Count | 2.4 (0.7) | 2.2 (0.6) | 2.2 (0.6) | 2.4 (0.8) | 2.2 (0.5) | 2.2 (0.6) | 0.78 |
| Absolute Monocyte Count | 0.5 (0.2) | 0.5 (0.2) | 0.5 (0.2) | 0.5 (0.1) | 0.5 (0.2) | 0.5 (0.2) | 0.92 |
| Absolute Eosinophil Count | 0.5 (0.2) | 0.4 (0.3) | 0.4 (0.2) | 0.4 (0.3) | 0.4 (0.2) | 0.4 (0.2) | 0.61 |
| CD203c Basophil Activation Test, mean (SD) † | |||||||
| PF 0.1 | 1.28 (0.40) | 1.14 (0.15) | 1.20 (0.18) | 1.42 (0.24) | 1.17 (0.17) | 1.20 (0.22) | 0.01 |
| PF 1 | 1.28 (0.27) | 1.28 (0.22) | 1.34 (0.25) | 1.49 (0.27) | 1.38 (0.24) | 1.32 (0.24) | 0.09 |
| PF 10 | 1.52 (0.52) | 1.66 (0.36) | 1.66 (0.40) | 1.88 (0.42) | 1.72 (0.40) | 1.67 (0.40) | 0.11 |
| PF 100 | 1.74 (0.66) | 1.85 (0.49) | 1.86 (0.51) | 2.02 (0.44) | 1.91 (0.36) | 1.86 (0.50) | 0.44 |
| PF 1000 | 1.73 (0.63) | 1.82 (0.48) | 1.75 (0.47) | 1.97 (0.44) | 1.86 (0.28) | 1.80 (0.47) | 0.39 |
| %CD63high Basophil Activation Test, median (IQR)† | |||||||
| PF 0.1 | 0.48 (1.02) | 0.60 (1.24) | 0.54 (0.81) | 0.45 (0.66) | 0.90 (1.18) | 0.55 (1.25) | 0.75 |
| PF 1 | 0.31 (0.62) | 1.66 (4.35) | 2.21 (3.24) | 2.06 (3.35) | 4.83 (5.83) | 1.92 (4.20) | 0.01 |
| PF 10 | 3.33 (6.63) | 10.70 (25.97) | 14.20 (18.37) | 12.60 (15.80) | 24.40 (19.80) | 11.90 (20.83) | 0.004 |
| PF 100 | 10.50 (25.61) | 24.00 (31.68) | 20.50 (30.99) | 9.59 (18.70) | 36.80 (22.50) | 22.40 (29.48) | 0.02 |
| PF 1000 | 6.82 (22.54) | 14.85 (25.04) | 13.50 (13.63) | 11.30 (17.68) | 14.90 (16.79) | 13.80 (18.85) | 0.24 |
| PF10/%CD63high anti-IgE | 0.46 (1.59) | 0.70 (1.42) | 1.51 (1.84) | 2.42 (7.57) | 1.93 (5.07) | 1.21 (1.82) | 0.01 |
| Antibodies (ng/L), median (IQR) | |||||||
| Peanut IgG4 (ug/L) | 430.0 (1870.0) | 1110.0 (2345.0) | 640.0 (930.0) | 450.0 (620.0) | 1600.0 (1220.0) | 830 (1,600) | 0.05 |
| Peanut IgE | 77.1 (277.7) | 178.9 (412.5) | 193.0 (478.0) | 21.9 (217.3) | 383.1 (614.6) | 192.9 (458.0) | 0.13 |
| Total IgE | 1342.0 (2364.4) | 1321.3 (2526.6) | 1149.2 (1766.6) | 592.9 (1461.6) | 1351.8 (2249.7) | 1284.7 (2379) | 0.49 |
| Peanut components (ng/L), median (IQR) | |||||||
| Ara h 1 | 27.3 (166.3) | 21.4 (115.1) | 57.1 (191.2) | 3.6 (15.5) | 179.6 (212.5) | 34.9 (177.8) | 0.18 |
| Ara h 2 | 39.3 (107.8) | 70.6 (209.5) | 87.1 (197.9) | 12.8 (140.9) | 196.7 (216.9) | 85.0 (207.1) | 0.09 |
| Ara h 3 | 0.9 (37.2) | 3.2 (22.2) | 9.7 (32.2) | 1.1 (5.3) | 25.9 (39.3) | 5.7 (38.6) | 0.31 |
| Ara h 8 | 0.0 (2.5) | 0.0 (2.5) | 0.0 (1.6) | 0.0 (0.6) | 0.0 (0.4) | 0.0 (1.8) | 0.95 |
| Ara h 9 | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 0.16 |
BAT, Basophil activation test; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DBPCFC, double-blind placebo-controlled food challenge
*
Kruskal-Wallis and Fisher’s exact tests were used to calculate p-values for continuous and categorical variables by CSS, respectively.
†
PF 100 indicates values for basophils stimulated with peanut flour at the 100 ng/mL concentration, etc.
‡
Collapsed CSS 5 and 6 due to only 1 subject in the CSS 6 category.